Inspire licenses anti-infective for $13M upfront

Inspire Pharmaceuticals has licensed the U.S. and Canadian commercialization rights to InSite Vision's anti-infective AzaSite. InSite gained $13 million in an upfront fee and will get a $19 million milestone payment on the FDA's approval of its NDA. AzaSite is designed to treat pink eye.

In a release, InSite CEO Kumar Chandrasekaran said that "this platform will allow us to pursue additional anti-infective products and indications worldwide, supported by our expanded patent portfolio for both the AzaSite and DuraSite technologies.

- here's the release on the licensing deal

Related Articles:
Side effects prompt Inspire to shutter trial. Report
Inspire shares plunge after FDA finds data insufficient. Report